US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SVB Financial Group

0.0060

+0.0000

Volume:- -

Turnover:- -

Market Cap:355.65K

PE:0.00

High:0.0060

Open:0.0060

Low:0.0060

Close:0.0060

Loading ...

Overview Company News Filings

BUZZ-Street View: Bristol Myers blows uptake opportunity with Cobenfy trial failure

BUZZ-Street View: Danaher well positioned to navigate tough macro environment

BUZZ-908 Devices rises after $2 million order from Texas Department of Public Safety

BUZZ-U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics

BUZZ-Certara jumps as FDA moves to replace animal testing

BUZZ-Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale

CORRECTED-UPDATE 1-Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says

CORRECTED-Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico in 2025, CFO says

BUZZ-Eli Lilly falls after rival Novo Nordisk reports next-gen obesity drug data

Silicon Valley Bank's former parent sues to reclaim tarnished brand

Silicon Valley Bank's former parent can pursue $1.93 billion FDIC lawsuit

BUZZ- Owens & Minor rises on plans to sell unit, Q4 profit beat

BUZZ-Intellia Therapeutics jumps on better-than-expected Q4 collaboration revenue

BUZZ-Street View: Mental health unit to weigh on Teladoc

BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period

BUZZ-Wall Street bullish on insulin device maker Beta Bionics after IPO

BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved

BUZZ-Hims & Hers jumps after buying at-home lab testing service

BUZZ-Arcus Biosciences falls on pricing $150 mln stock offering at 16% discount

Vouch raises Allegis-led Series D and agrees to acquire startup-focused MGA StartSure

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SIVBQ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SIVBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIVBQ\",,,,,undefined,":{"symbol":"SIVBQ","market":"US","secType":"STK","nameCN":"SVB Financial Group","latestPrice":0.006,"timestamp":1746041040000,"preClose":0.006,"halted":0,"volume":0,"delay":15,"floatShares":53990110,"shares":59274992,"eps":25.35,"marketStatus":"Trading","change":0,"latestTime":"04-30 15:24:00 EDT Delay","open":0.006,"high":0.006,"low":0.006,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":25.35,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"exchange":"EXPERT","adjPreClose":0.006,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIVBQ\",,,,,undefined,":{"symbol":"SIVBQ","floatShares":53990110,"roa":"0.76%","roe":"9.78%","lyrEps":25.581907,"shares":59274992,"dividePrice":0,"high":0.006,"amplitude":0,"preClose":0.006,"low":0.006,"week52Low":0.0011,"pbRate":"0.00","psRate":"0.00","week52High":0.13,"institutionHeld":0,"latestPrice":0.006,"eps":25.35,"divideRate":0,"volume":0,"delay":15,"ttmEps":25.35,"open":0.006,"prevYearClose":0.006,"prevWeekClose":0.006,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.006,"twentyDayClose":0.006,"sixtyDayClose":0.006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SIVBQ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529657686","title":"BUZZ-Street View: Bristol Myers blows uptake opportunity with Cobenfy trial failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2529657686","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529657686?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:26","pubTimestamp":1745414807,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Bristol Myers blows uptake opportunity with Cobenfy trial failure** Bristol Myers Squibb BMY.N said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand its use as an add on treatment for schizophrenia ** Median PT of brokerages covering the stock is $55.50, per data compiled by LSEGMODEST EFFICACY ** Leerink Partners  says the adjunctive trial failure demonstrates Cobenfy's efficacy is modest which could mean far less potential than was originally anticipated** William Blair  says the trial blows an opportunity to accelerate the uptake of Cobenfy overall by increasing physician confidence in the drug as a secondary treatment ahead of their own personalized approaches** BMO Capital Markets  says it anticipates some continued modest use of Cobenfy given the limited number of options in the adjunctive setting** Jefferies  says it is still optimistic of Cobenfy in patients with psych","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R11CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","BK4207","IE00BJJMRZ35.SGD","LU0882574055.USD","LU2360032135.SGD","BK4585","LU1430594728.SGD","BK4007","LU1868837136.USD","LU0225284248.USD","BK4581","LU0985481810.HKD","LU1670710588.SGD","BK4211","LU1670710661.SGD","LU1670711123.USD","LU2242646821.SGD","LU1868836914.USD","IE00BSNM7G36.USD","BK4532","BK4559","LU1032466523.USD","LU1868837300.USD","LU0321505868.SGD","LU1074936037.SGD","LU1261432733.SGD","LU0306806265.USD","LU0096364046.USD","BK4127","LU1585245621.USD","LU1989771016.USD","BMY","LU1093756325.SGD","JEF","LU0225771236.USD","LU1868836591.USD","LU2125154778.USD","LU0114720955.EUR","LU1718418525.SGD","IE00BJT1NW94.SGD","LU1670711040.USD","LU2125154935.USD","LU1323610961.USD","LU2133065610.SGD","LU0868494617.USD","SIVBQ","BK4588","LU0456855351.SGD","BK4589","LU0321505439.SGD"],"gpt_icon":0},{"id":"2529322501","title":"BUZZ-Street View: Danaher well positioned to navigate tough macro environment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529322501","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529322501?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:40","pubTimestamp":1745408413,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Danaher well positioned to navigate tough macro environment** Danaher DHR.N beat Wall Street estimates for first-quarter profit on Tuesday, and said it expects to incur additional tariff-related costs of about $350 million this year** Median PT of brokerages covering the stock is $246.50, per data compiled by LSEG     ABLE TO NAVIGATE TOUGH ENVIRONMENT   ** Leerink Partners  says it sees DHR as the leader in the recurring revenue market of bioprocess tools** William Blair  says Danaher is well insulated from broader macro headwinds ** Evercore ISI  says underlying order momentum and backlog build was a solid data point that suggests order patterns normalizing ** RBC Capital Markets  says DHR's positive Q1 results provides a much-needed piece of good news for the sector ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R111M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0528227936.USD","IE00BZ1G4Q59.USD","BK4581","LU0114720955.EUR","SG9999001176.SGD","LU0672654240.SGD","LU1023059063.AUD","BK4207","BK4534","LU2125909247.SGD","LU2125910336.SGD","IE0004445239.USD","LU0820561818.USD","LU0289960550.SGD","LU1804176565.USD","LU1917777945.USD","SGXZ23171101.USD","EVR","LU0820561909.HKD","BK4589","SG9999013999.USD","LU0689472784.USD","LU2112291526.USD","LU0320765059.SGD","BK4121","LU1791710582.SGD","IE00BKVL7J92.USD","BK4533","LU1057294990.SGD","IE000M9KFDE8.USD","BK4211","DHR","LU2106854487.HKD","LU0943347566.SGD","LU2265009873.SGD","LU0390134368.USD","LU0175139822.USD","LU0511384066.AUD","LU0109391861.USD","LU2023250504.SGD","LU2125909593.SGD","LU0107464264.USD","SGXZ57979304.SGD","SIVBQ","LU0312595415.SGD","LU0289739343.SGD","LU2063271972.USD","LU2355687059.USD","BK4588"],"gpt_icon":0},{"id":"2529730977","title":"BUZZ-908 Devices rises after $2 million order from Texas Department of Public Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2529730977","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529730977?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:30","pubTimestamp":1745325048,"startTime":"0","endTime":"0","summary":"BUZZ-908 Devices rises after $2 million order from Texas Department of Public Safety** Shares of chemical detector maker 908 Devices MASS.O up 4.2% at $5 premarket ** MASS says it has received a $2 million order from the Texas Department of Public Safety for its MX908 device for drug detection and mitigation** Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis** MX908 device detects and identifies hazardous substances, including chemicals, explosives and aerosolized threats, at trace levels** Company says the order will be shipped in April** With this order, MASS can achieve 25% of the midpoint of their guidance, positioning them well for the typically strong H2 2025 - Brokerage Leerink Partners ** Brokerage adds \"This order gives us added confidence in MASS' ability to progress towards their guide after co has had to lower guidance in prior years\"** As of last close, MASS had rise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL4N3R0102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4589","MASS","BK4211","BK4207","BK4157","BK4585","SIVBQ","BK4588"],"gpt_icon":0},{"id":"2528527322","title":"BUZZ-U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528527322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528527322?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:02","pubTimestamp":1744826527,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General DynamicsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL6N3QU0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVX","UAL","MPC","SIVBQ","URGN","CYD","GO","SNVD.UK","NEM","GD","03888","CFG","TGL","ICAD","MOV","FRGE","ABT","ALV","HTZ","CLIK","FANG","LYFT","HWC","OMC","APA","JBHT","KKR","NEE","XOM","NOVA","NVIW.SI","TRV","OST","RGLD","PLD","NVDY","CALM","AREC","BLUE","DVN"],"gpt_icon":1},{"id":"2526833540","title":"BUZZ-Certara jumps as FDA moves to replace animal testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526833540","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526833540?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:42","pubTimestamp":1744321355,"startTime":"0","endTime":"0","summary":"BUZZ-Certara jumps as FDA moves to replace animal testing** Shares of drug developer Certara CERT.O up 29.3% at $13.59 in extended trading** U.S. FDA says it plans to replace animal testing with \"human-relevant methods\", including AI-based models, to improve drug safety and lower costs, and will start implementing this new approach immediately** Analysts at brokerage Leerink Partners say FDA's announcement is a \"clear incremental positive\" for CERT, as its biosimulation capabilities may see higher demand, although \"ultimate upside is unclear\"** Leerink Partners adds that CERT's biosimulation platform \"takes on incremental value\", as it could be a replacement or add-on to animal testing ** Brokerage also sees Labcorp's LH.N 5% decline, at market close, as an \"overreaction\" to FDA's announcement, since early development  business is \"not entirely animal-based\" and animal testing isn't ending immediately** ED business's contribution to LH's overall revenue is relatively small, at around 6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL3N3QO1LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH","BK4585","LU0742534661.SGD","BK4207","BK4196","BK4589","LU0251131958.USD","SIVBQ","LU0048573561.USD","LU0251142724.SGD","LU1059921491.USD","BK4167","LU0006061336.USD","CERT","BK4588","BK4211","BK4550"],"gpt_icon":0},{"id":"2520243256","title":"BUZZ-Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2520243256","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520243256?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:47","pubTimestamp":1742467626,"startTime":"0","endTime":"0","summary":"BUZZ-Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale** Shares of Akebia Therapeutics AKBA.O down 26.1% at $2.10 before the bell after co raises equity at steep discount** Cambridge, Massachusetts-based co focused on kidney disease late Weds announced pricing of 25 mln shares at $2 for $50 mln gross proceeds** Offering priced at 29.6% discount to last sale** AKBA shares rose ~11% on Weds, capping a four-session winning streak in which they racked up a 68% gain** On Mar 13, co reported Q4 results and said it expects its anemia drug, branded as Vafseo, to generate $10-$11 mln of net product revs in Q1** Co to use net offering proceeds to fund working capital and general corporate purposes, including R&D and commercial activities for its products and pipeline candidates, per the SEC prospectus filing** With ~236.2 mln shares outstanding, per the latest 10-K filing, AKBA has ~$670 mln market cap** Leerink Partners and Piper Sandler are jt bookrunners for the stock offering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL6N3Q30D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4207","BK4139","BK4127","BK4585","SIVBQ","BK4588","PIPR","AKBA","BK4589"],"gpt_icon":0},{"id":"2518220467","title":"CORRECTED-UPDATE 1-Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220467","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518220467?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:17","pubTimestamp":1741616226,"startTime":"0","endTime":"0","summary":"CORRECTED-UPDATE 1-Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO saysCorrects headline and story to say the treatment will be launched in 2025, not 2026. March 10  - Eli Lilly LLY.N plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.\"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro,\" Montarce said at the Leerink Partners Global Healthcare Conference.Global demand for Lilly's and Danish rival Novo Nordisk's NOVOb.CO diabetes and weight-loss drugs has been extraordinary, with the two companies delaying their entry into new and emerging markets until they scaled up supply.Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weightloss. However, it is sold under the brand name Zepbound for obesity in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT13F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","LU1804176565.USD","LU2361044949.HKD","LU2237443622.USD","LU0114720955.EUR","IE00B1BXHZ80.USD","LU2357305700.SGD","LU0289739699.SGD","LU2237443895.HKD","SIVBQ","IE00BJLML261.HKD","LU0672654240.SGD","LU1551013425.SGD","LU2461242641.AUD","LLY","LU0823416689.USD","LU0640476718.USD","LU2324357040.USD","LU1280957306.USD","LU1974910355.USD","LU0820561909.HKD","BK4581","LU1023059063.AUD","LU1983299246.USD","SGXZ31699556.SGD","BK4516","LU1868836591.USD","LU1868837136.USD","LU2360106947.USD","BK4533","LU0256863902.USD","SG9999001176.SGD","LU0882574055.USD","SG9999013999.USD","LU0354030438.USD","LU0466842654.USD","LU0820561818.USD","LU0256863811.USD","LU0097036916.USD","LU2468319806.SGD","LU1267930730.SGD","SG9999014880.SGD","IE00BK4W5M84.HKD","LU0708995401.HKD","SGXZ57979304.SGD","LU2265009873.SGD","LU2106854487.HKD","LU1720051108.HKD","BK4589","LU0354030511.USD"],"gpt_icon":1},{"id":"2518522204","title":"CORRECTED-Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico in 2025, CFO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2518522204","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518522204?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:48","pubTimestamp":1741614499,"startTime":"0","endTime":"0","summary":"CORRECTED-Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico in 2025, CFO saysCorrects headline and story to say the treatment will be launched in 2025, not 2026March 10  - Eli Lilly LLY.N plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday at the Leerink Partners Global Healthcare Conference.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT12I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","LU1868837300.USD","SG9999001176.SGD","LU1064131342.USD","LLY","SIVBQ","LU0122379950.USD","SGXZ81514606.USD","LU2112291526.USD","LU1814569148.SGD","LU2361044949.HKD","LU2461242641.AUD","LU1127390331.HKD","LU2237443549.SGD","LU0882574139.USD","BK4516","LU2237438978.USD","SG9999014906.USD","BK4207","SGXZ99366536.SGD","BK4589","LU0672654240.SGD","LU1093756325.SGD","BK4599","LU1551013425.SGD","LU1868836757.USD","SG9999013999.USD","LU1868837136.USD","LU0238689110.USD","LU0823416689.USD","LU2265009873.SGD","LU2237443465.HKD","LU1720051017.SGD","LU2237443978.SGD","LU2360106947.USD","SG9999017495.SGD","BK4588","LU1023059063.AUD","LU1720051108.HKD","SG9999015945.SGD","LU2491050154.USD","LU2089984988.USD","SG9999018865.SGD","LU0058720904.USD","SG9999015986.USD","LU0106261372.USD","LU0466842654.USD","LU0354030438.USD","SGXZ57979304.SGD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2518226308","title":"BUZZ-Eli Lilly falls after rival Novo Nordisk reports next-gen obesity drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226308?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:43","pubTimestamp":1741610627,"startTime":"0","endTime":"0","summary":"BUZZ-Eli Lilly falls after rival Novo Nordisk reports next-gen obesity drug data** Shares of U.S. drugmaker Eli Lilly LLY.N fall 1.5% to $856.37 premarket** Danish rival Novo Nordisk NOVOb.CO reports late-stage data for its experimental next-generation weight-loss drug, CagriSema ** Says CagriSema helped overweight patients with type 2 diabetes  cut their weight by 15.7% after 68 weeks compared to 3.1% with placebo ** This compares to absolute weight loss of up to ~15.5% shown by LLY's obesity drug Zepbound in T2D patients at week 68 in a late-stage study - Brokerage Leerink Partners** The CagriSema weight loss data appears a comparable cross-trial to LLY's Zepbound, brokerage says** Up to last close, LLY stock had risen 11.5% in the past 12 months   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","LU2357305700.SGD","LU2264538146.SGD","LU0238689110.USD","IE00B2B36J28.USD","LU1093756168.USD","LU0354030511.USD","IE00B1BXHZ80.USD","LU1988902786.USD","LU1023059063.AUD","SG9999014914.USD","LU0122379950.USD","LU0058720904.USD","LU1093756325.SGD","LU0097036916.USD","LU1917777945.USD","LU1720051108.HKD","IE00BK4W5M84.HKD","LU2361044865.SGD","LU2491050154.USD","LU0640476718.USD","LLY","BK4211","LU0882574139.USD","SGXZ81514606.USD","LU2237443549.SGD","LU0466842654.USD","LU1366192091.USD","LU1291159041.SGD","LU1814569148.SGD","LU2602419157.SGD","LU2324357040.USD","LU0114720955.EUR","SG9999015952.SGD","LU2237443465.HKD","LU1127390331.HKD","LU1551013342.USD","LU2237443622.USD","LU1974910355.USD","SG9999014898.SGD","SIVBQ","SG9999014880.SGD","LU2237443978.SGD","IE0004445239.USD","SG9999015986.USD","IE00BK4W5L77.USD","LU1267930730.SGD","LU2106854487.HKD","BK4534","LU0823416689.USD"],"gpt_icon":1},{"id":"2517229927","title":"Silicon Valley Bank's former parent sues to reclaim tarnished brand","url":"https://stock-news.laohu8.com/highlight/detail?id=2517229927","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517229927?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:21","pubTimestamp":1741213272,"startTime":"0","endTime":"0","summary":"Silicon Valley Bank's former parent sues to reclaim tarnished brandBy Jonathan Stempel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL2N3PO16G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1551013342.USD","IE00B1XK9C88.USD","LU1720051017.SGD","LU2756315318.SGD","LU0976567544.SGD","LU0006061336.USD","LU0106831901.USD","LU1244550577.SGD","LU0964807845.USD","LU0211326839.USD","LU1119994496.HKD","LU2237443382.USD","LU2237443978.SGD","BK4566","FCNCA","LU2213496289.HKD","IE00BN8TJ469.HKD","LU2430703095.HKD","LU0320765646.SGD","IE00BFXG1179.USD","IE00BBT3K403.USD","LU2242649171.HKD","LU0072461881.USD","LU0070302665.USD","FIZN","LU1084165304.USD","BK4550","LU0417517546.SGD","SG9999002232.USD","LU0943347566.SGD","BK4589","SIVBQ","LU2505996509.AUD","LU1032466523.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU1366192091.USD","LU1894683348.USD","IE00BDCRKT87.USD","LU2756315664.SGD","IE0034235295.USD","LU1363072403.SGD","LU2237443622.USD","LU0787776722.HKD","LU1244550494.USD","IE00BLSP4452.SGD","BK4581","LU0208291251.USD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2514496376","title":"Silicon Valley Bank's former parent can pursue $1.93 billion FDIC lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2514496376","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514496376?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:53","pubTimestamp":1740758005,"startTime":"0","endTime":"0","summary":"Silicon Valley Bank's former parent can pursue $1.93 billion FDIC lawsuitBy Jonathan Stempel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL2N3PJ0PF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072461881.USD","BK4585","FIZN","LU0006061336.USD","SIVBQ","BK4211","LU0162691827.USD","BK4207","BK4589","FCNCA","BK4588"],"gpt_icon":0},{"id":"2514832183","title":"BUZZ- Owens & Minor rises on plans to sell unit, Q4 profit beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832183","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832183?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:10","pubTimestamp":1740748209,"startTime":"0","endTime":"0","summary":"BUZZ- Owens & Minor rises on plans to sell unit, Q4 profit beat ** Shares of medical supplies distributor Owens & Minor OMI.N rise 10.3% to $7.6 premarket** Co's Q4 profit beats estimates and OMI says","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4589","BK4211","SIVBQ","BK4585","BK4588","OMI","BK4175"],"gpt_icon":0},{"id":"2514438741","title":"BUZZ-Intellia Therapeutics jumps on better-than-expected Q4 collaboration revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514438741?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:42","pubTimestamp":1740674569,"startTime":"0","endTime":"0","summary":"BUZZ-Intellia Therapeutics jumps on better-than-expected Q4 collaboration revenue** Shares of Massachusetts-based gene-editing firm Intellia Therapeutics NTLA.O up 8.4% at $11.71** Company posts Q4 collaboration revenue of $12.9 million, beating analysts' estimates of $8.5 million, according to data compiled by LSEG ** Company's sales was mainly driven by collaboration revenue received under the Regeneron REGN.O agreements to develop gene-editing therapies for neurological and muscular disease. ** Brokerage Leerink Partners expects shares to rise in the mid-single digits as company fleshed out details including operating expenses on call; NTLA expects 5%-10% lower operating expenses vs a year ago","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI1Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","NTLA","SIVBQ"],"gpt_icon":0},{"id":"2514882863","title":"BUZZ-Street View: Mental health unit to weigh on Teladoc","url":"https://stock-news.laohu8.com/highlight/detail?id=2514882863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514882863?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:21","pubTimestamp":1740666118,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Mental health unit to weigh on Teladoc** Telehealth company Teladoc Health TDOC.N late on Wednesday reported a wider loss and a disappointing forecast amid challenges at its mental health division BetterHelp** Shares fell 13.38% to $9.51 in premarket trading'2025 IMPORTANT FOR TURNAROUND'** Leerink Partners  says the biggest concern from the results is the lack of cost leverage expected for 2025, says this is an underlying challenge for BetterHelp in the direct-to-consumer market** Jefferies  says BetterHelp is expected to remain under pressure in 2025** TD Cowen says expectations for BetterHelp were low, believes a path to turnaround the segment remains unclear** J.P.Morgan expects TDOC will remain an execution story in the eyes of investors, says 2025 is important for its turnaround  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI1C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","LU0323591593.USD","LU1629891620.HKD","BK4167","LU1974910355.USD","LU2242649171.HKD","LU1917777945.USD","LU0048584097.USD","LU1496350171.SGD","LU1084165304.USD","LU1861559042.SGD","LU1894683348.USD","LU1670627923.USD","LU2430703251.USD","IE00B775SV38.USD","LU2430703095.HKD","LU2592432038.USD","LU0820561818.USD","LU0211326839.USD","LU2213496289.HKD","BK4534","LU0787776722.HKD","IE0034235295.USD","LU0215105999.USD","TDOC","LU0820562030.AUD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","LU0211326755.USD","LU0683600562.USD","SIVBQ","BK4516","LU0234572021.USD","SG9999002224.SGD","LU0208291251.USD","LU1720051108.HKD","LU2505996681.GBP","IE00B1XK9C88.USD","LU0149725797.USD","LU0238689110.USD","LU0820561909.HKD","LU2552382215.SGD","LU1551013425.SGD","LU2023250504.SGD","LU0882574139.USD","LU2023250330.USD","JEF","LU2237443549.SGD","SG9999002232.USD"],"gpt_icon":1},{"id":"2514968019","title":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period","url":"https://stock-news.laohu8.com/highlight/detail?id=2514968019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514968019?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:13","pubTimestamp":1740499987,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34 ** Wall Street brokerages start coverage of the drug de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG1OA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4588","BK4211","MAZE","BK4589","BK4207","SIVBQ"],"gpt_icon":0},{"id":"2513787567","title":"BUZZ-Wall Street bullish on insulin device maker Beta Bionics after IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2513787567","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513787567?lang=en_us&edition=fundamental","pubTime":"2025-02-24 23:34","pubTimestamp":1740411293,"startTime":"0","endTime":"0","summary":"BUZZ-Wall Street bullish on insulin device maker Beta Bionics after IPO** Wall Street brokerages start coverage of insulin device maker, Beta Bionics BBNX.O, on a bullish note as IPO research quiet pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF12B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","LU0320765646.SGD","LU0321505439.SGD","SIVBQ","LU0149725797.USD","LU1718418525.SGD","LU0053666078.USD","LU0683600562.USD","LU0980610538.SGD","BK4211","LU1880398471.USD","LU1366192091.USD","LU1201861249.SGD","LU1496350171.SGD","LU1894683264.USD","BK4207","LU1267930227.SGD","LU0477156797.USD","IE00BFXG1179.USD","BK4588","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0321505868.SGD","BBNX","LU0417517546.SGD","BK4589","LU0130518102.USD","BK4553","IE00B19Z3581.USD","LU0971096721.USD","LU0234572021.USD","BK4504","LU0130103400.USD","LU1894683348.USD","LU0170899867.USD","LU2133065610.SGD","BK4581","BK4585","IE00BLSP4452.SGD","LU0306807586.USD","LU0640476718.USD","LU0787776722.HKD","LU2129689605.HKD","BAC","LU0306806265.USD","IE00BLSP4239.USD","LU0648000940.SGD","BK4559","LU1074936037.SGD","LU1162221912.USD"],"gpt_icon":1},{"id":"2513291974","title":"BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513291974?lang=en_us&edition=fundamental","pubTime":"2025-02-21 23:23","pubTimestamp":1740151429,"startTime":"0","endTime":"0","summary":"BUZZ-Hims and Hers falls as US shortage of Novo's weight loss drug is resolved ** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC1D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4585","HIMS","BK4196","BK4588","BK4589","BK4207","SIVBQ"],"gpt_icon":1},{"id":"2512964484","title":"BUZZ-Hims & Hers jumps after buying at-home lab testing service","url":"https://stock-news.laohu8.com/highlight/detail?id=2512964484","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512964484?lang=en_us&edition=fundamental","pubTime":"2025-02-20 00:37","pubTimestamp":1739983041,"startTime":"0","endTime":"0","summary":"BUZZ-Hims & Hers jumps after buying at-home lab testing service** Shares of telehealth firm Hims and Hers HIMS.N rise 16.1% to $67.94 ** Co acquires at-home lab testing service Trybe Labs, which offer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nL3N3PA10K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","BK4196","BK4588","BK4211","BK4589","BK4585","BK4207","SIVBQ"],"gpt_icon":1},{"id":"2512159061","title":"BUZZ-Arcus Biosciences falls on pricing $150 mln stock offering at 16% discount","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159061","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159061?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:21","pubTimestamp":1739881291,"startTime":"0","endTime":"0","summary":"BUZZ-Arcus Biosciences falls on pricing $150 mln stock offering at 16% discount** Arcus Biosciences shares RCUS.N drop 4% to $12.57 premarket** Arcus's 13.6 mln stock offering priced at $11 each, a 16% discount to last close** Co plans to use gross proceeds of ~$150 mln to develop its experimental kidney cancer drug and for other purposes** Goldman Sachs, Leerink Partners and Evercore ISI were joint book-runners** Prior to offering, RCUS had 91.5 mln outstanding shares for $1.20 bln market cap, per LSEG data  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nL3N3P90W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4589","BK4139","LU2471134796.USD","LU2750360641.GBP","IE0004086264.USD","LU2237443978.SGD","LU1868836757.USD","LU2750360997.AUD","LU0106831901.USD","BK4504","BK4552","LU2471134879.HKD","IE00BSNM7G36.USD","LU1868837300.USD","BK4533","LU2237443549.SGD","LU1868836591.USD","IE00B19Z3B42.SGD","LU2471134523.USD","BK4516","BK4585","IE0034235188.USD","LU2237438978.USD","LU1868837136.USD","LU2237443382.USD","IE0002270589.USD","LU0096364046.USD","BK4211","LU2237443465.HKD","RCUS","EVR","LU1668664300.SGD","LU1868836914.USD","LU2237443895.HKD","SIVBQ","LU2471134952.CNY","BK4588","IE00B19Z3581.USD","LU2237443622.USD","BK4550","BK4127","LU1791807156.HKD","BK4207","IE0004091025.USD","IE00BFXG1179.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2511237705","title":"Vouch raises Allegis-led Series D and agrees to acquire startup-focused MGA StartSure","url":"https://stock-news.laohu8.com/highlight/detail?id=2511237705","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511237705?lang=en_us&edition=fundamental","pubTime":"2025-02-13 22:30","pubTimestamp":1739457005,"startTime":"0","endTime":"0","summary":"Vouch raises Allegis-led Series D and agrees to acquire startup-focused MGA StartSureBy James ThalerFeb 13 - (The Insurer) - Startup-focused insurtech Vouch has sealed a first close on an Allegis Capi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nL6N3P40JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4589","BK4019","BK4211","SPNT","BK4207","BK4585","SIVBQ","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SIVBQ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-08","symbol":"SIVBQ","reason":null,"defaultRemindTime":1731076200000,"announcedDate":null,"type":"delisting","dateTimestamp":1731042000000},{"market":"US","date":"2023-10-19","symbol":"SIVBQ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1697688000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SIVBQ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SIVBQ\",market:\"US\",delay:true,,,undefined,":{}}}